Skip to main content
. 2023 Jan 29;15(3):819. doi: 10.3390/cancers15030819

Figure 1.

Figure 1

DHEA treatment reduces breast cancer cell motility and invasion. (A) MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay in MDA-MB-231 and MDA-MB-436 breast cancer cells treated as indicated for 24 h. (B) IC50 values of DHEA in MDA-MB-231 (MDA-231) and MDA-MB-436 (MDA-436) cells from MTT growth assay after 24 h. (C) Wound healing assay in MDA-MB-231 and MDA-MB-436 cells treated with vehicle (−) or DHEA 10 µM. Time 0 is shown. Pictures are representative of three independent experiments. Boyden chamber transmigration (D,E) invasion assays in MDA-MB-231 and MDA-MB-436 cells treated with vehicle (−) or DHEA 10 µM within 24 h. The values represent the mean ±SEM of three different experiments. * p < 0.05; ** p < 0.005; *** p < 0.0005; **** p < 0.0001.